Bristol Myers Squibb (BMS) and Chinese biopharma company Hengrui Pharma have inked one of the largest licensing and collaboration deals in the industry’s history, centering around several early-stage oncology, immunology and haematology assets.
The appointment marks a planned transition in leadership structure to continue to build on the company’s success. A combination of organic growth and targeted acquisitions has led Symeres to evolve into a fully integrated transatlantic partner.
Sun Pharma’s recent, nearly $12 billion acquisition reflects growing global ambitions of India’s pharma industry to evolve from its roots in the generics market. But is the country poised for a China-esque pivot toward becoming a powerhouse of innovation?
Through this exclusive agreement, GSK will secure the global rights to the Chinese biotechs early-stage, potential first-in-disease small interfering RNA (siRNA) therapy, SA030, outside of China, Hong Kong, Macau and Taiwan.
The Belgian pharmaceutical giant reached a deal to acquire Candid Therapeutics, a startup developing “bispecifics,” or double-barreled antibodies. UCB is paying $2 billion in upfront cash for Candid, and could add another $200 million in future milestone payments. The deal is expected to close by the end of the second quarter or shortly thereafter.
